Danske Bank A S Takes $32.35 Million Position in Axon Enterprise, Inc $AXON

Danske Bank A S bought a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 57,710 shares of the biotechnology company’s stock, valued at approximately $32,353,000. Danske Bank A S owned about 0.07% of Axon Enterprise as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in AXON. Evergreen Capital Management LLC boosted its stake in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the period. Synergy Financial Group LTD raised its holdings in Axon Enterprise by 1.4% during the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after buying an additional 19 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Axon Enterprise by 1.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock valued at $1,350,000 after buying an additional 19 shares during the period. Certuity LLC grew its holdings in Axon Enterprise by 5.1% in the 4th quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 23 shares during the last quarter. Finally, Pure Financial Advisors LLC grew its holdings in Axon Enterprise by 6.7% in the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Barclays lifted their price objective on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Piper Sandler raised their target price on Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $715.00 price target on shares of Axon Enterprise in a research note on Thursday, August 6th. Finally, Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $730.92.

Insider Transactions at Axon Enterprise

In other news, insider Elizabeth Reid Coughlin sold 1,554 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the sale, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. This represents a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Patrick W. Smith sold 9,930 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $548.77, for a total value of $5,449,286.10. Following the transaction, the chief executive officer owned 3,031,067 shares of the company’s stock, valued at $1,663,358,637.59. The trade was a 0.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 68,989 shares of company stock valued at $36,016,932. 4.20% of the stock is currently owned by corporate insiders.

Axon Enterprise Price Performance

AXON stock opened at $645.72 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The firm has a 50 day moving average price of $536.03 and a 200-day moving average price of $474.89. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $794.29. The firm has a market capitalization of $52.46 billion, a price-to-earnings ratio of 267.93, a PEG ratio of 10.06 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. The firm’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.12 EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.